Table 1 (abstract P218). Process and outcome measure definitions for a Lupus Treat to Target Intervention
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Implementation Phase | Estimated Length of Time | Measure Title |
|---|---|---|
Pre-Work, Phase 0 | 3 months | Implementation science measures (appropriateness, acceptability, feasibility) |
Process Measures, Phase 1 | 6 months | SLE Disease Activity Index (SLEDAI) completion New disease activity attestation Physician global assessment (0-3) completion Prednisone dose documented |
Process Measures, Phase 2 | 6 months | Disease activity target set Steroid dose target set Provider attestation of disease activity status Provider attestation of steroid dose status |
Outcome Measures, Phase 3 | 3 months | LLDAS criteria met SLEDAI-2K ≤ 4 Prednisone dose (continuous, dichotomous) |
Balancing Measures, Phase 3 | 3 months | New disease activity Steroid dose escalation |
Sustain Phase, Phase 4 | ongoing | All of the above |